Pune, Jan. 11, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Cancer Profiling Market is expected to clock US$ 23.7 billion by 2031 and to grow at a CAGR of 10.54% during the forecast period.
The Cancer Profiling Market is driving a paradigm shift in oncology by leveraging advanced technologies to profile and understand the intricacies of cancer at a molecular level. This press release sheds light on key developments, breakthroughs, and the dynamic landscape of the Cancer Profiling Market, contributing to the era of precision oncology and personalized cancer treatment.
Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/cancer-profiling-market/8424
Cancer Profiling Market Scope
| Report Attribute | Details |
| Market size value in 2022 | US$ 10.6 billion |
| Revenue forecast in 2031 | US$ 23.7 billion |
| CAGR | 10.54% |
| Base Year for Estimation | 2022 |
| Forecast Period | 2023-2031 |
| Historical Year | 2021 |
| Segments Covered | Cancer Type, Technology, Biomarker, Application and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Molecular Profiling for Personalized Treatment: The Cancer Profiling Market centers around molecular profiling, a process that involves analyzing the genetic, genomic, and proteomic characteristics of a tumor. This in-depth analysis enables healthcare professionals to understand the unique molecular signatures of individual cancers, paving the way for personalized treatment strategies tailored to each patient's specific cancer profile.
Comprehensive Genomic Sequencing (CGS): Comprehensive Genomic Sequencing (CGS) is a cornerstone of cancer profiling, providing a comprehensive view of the genetic alterations within a tumor. CGS allows for the identification of specific mutations, gene fusions, and other genomic abnormalities that drive cancer growth. The insights derived from CGS empower oncologists to make informed decisions about targeted therapies and immunotherapies.
Liquid Biopsy for Non-Invasive Monitoring: The Cancer Profiling Market embraces liquid biopsy as a non-invasive method for cancer monitoring and profiling. Liquid biopsy involves analyzing circulating tumor DNA (ctDNA) or other biomarkers in the blood to detect genetic alterations indicative of cancer. This approach offers a less invasive alternative to traditional tissue biopsies and allows for real-time monitoring of cancer dynamics.
Immunoprofiling and Immunotherapy Selection: Immunoprofiling is a pivotal aspect of cancer profiling, focusing on understanding the tumor microenvironment and the interaction between cancer cells and the immune system. This information is crucial for selecting appropriate immunotherapies that harness the body's immune system to target and eliminate cancer cells. The Cancer Profiling Market plays a key role in advancing precision immunotherapy approaches.
Integration of Artificial Intelligence (AI): The Cancer Profiling Market is witnessing the integration of Artificial Intelligence (AI) to enhance data analysis and interpretation. AI algorithms can analyze vast datasets generated through molecular profiling, identifying patterns and potential therapeutic targets more efficiently. This accelerates the decision-making process and contributes to the ongoing refinement of precision oncology strategies.
Stratification for Clinical Trials: Cancer profiling is instrumental in patient stratification for clinical trials. By identifying specific molecular characteristics, patients can be matched with clinical trials testing targeted therapies or experimental treatments that align with their cancer profile. This approach increases the likelihood of treatment response and contributes to the success of clinical trials.
Collaborative Research and Data Sharing: Collaboration and data sharing are fundamental principles in the Cancer Profiling Market. Researchers, healthcare institutions, and biotechnology companies collaborate to pool resources, share datasets, and collectively advance our understanding of cancer biology. This collaborative ethos accelerates research and facilitates the development of novel therapeutic interventions.
Challenges and Opportunities: Challenges in the Cancer Profiling Market include data interpretation complexities, standardization of profiling methodologies, and the need for expanded accessibility to advanced profiling technologies. Opportunities for advancements lie in ongoing research, technological refinements, and initiatives to make cancer profiling more accessible globally.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecast Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- Reimbursement Scenario
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL CANCER PROFILING MARKET - ANALYSIS & FORECAST, BY CANCER TYPE
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma Cancer
- Other Cancer
- GLOBAL CANCER PROFILING MARKET - ANALYSIS & FORECAST, BY TECHNOLOGY
- Immunoassay
- Next Generation Sequencing
- Polymerase Chain Reaction
- Mass Spectrometry
- In-Situ Hybridization
- Microarrays
- Others
- GLOBAL CANCER PROFILING MARKET - ANALYSIS & FORECAST, BY BIOMARKER
- Genomic Biomarker
- Protein Biomarker
- Other Biomarker
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8424
Future Outlook: The Cancer Profiling Market is poised for continuous growth and innovation, shaping the future of oncology. Ongoing research, technological advancements, and a commitment to addressing challenges are pivotal in realizing the full potential of cancer profiling. The market's evolution positions it as a key driver in advancing precision oncology and improving patient outcomes.
Browse other reports:
According to the deep-dive market assessment study by Growth Plus Reports, the global cosmetic bioactive ingredients market was valued at US$ 1.52 billion in 2021 and is expected to register a revenue CAGR of 5.35% to reach US$ 2.44 billion by 2030.
According to the deep-dive market assessment study by Growth Plus Reports, the global immunohematology market was valued at US$ 12.71 billion in 2021 and is expected to register a revenue CAGR of 5.10% to reach US$ 19.49 billion by 2030.
According to the deep-dive market assessment study by Growth Plus Reports, the global neonatal intensive care respiratory devices market was valued at US$ 11.5 billion in 2021 and is expected to register a revenue CAGR of 5.05 % US$ 17.92 billion by 2030.
According to the deep-dive market assessment study by Growth Plus Reports, the global orthopedic trauma fixation devices market was valued at US$ 8.5 billion in 2021 and is expected to register a revenue CAGR of 4.4% to reach US$ 12.52 billion by 2030.
The global pharmaceuticals and food anti-counterfeiting technologies market was valued at US$ 172.91 billion in 2021 and is expected to register a revenue CAGR of 7.9% to reach US$ 342.78 billion by 2030.
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
